The mechanism for inflammation associated tumor development is a central issue for tumor biology and immunology and remains to be fully elucidated. Although IL-17 is implicated in association with inflammation mediated carcinogenesis, mechanisms are largely elusive. In the current studies, we showed that IL-17 receptor-A gene deficient (IL-17R-/-) mice were resistant to chemical carcinogen-induced cutaneous carcinogenesis, a well-established inflammation associated tumor model in the skin. The deficiency in IL-17R increased the infiltration of CD8+ T cells whereas it inhibited the infiltration of CD11b+ myeloid cells and development of myeloid derived suppressor cells. Inflammation induced skin hyperplasia and production of pro-tumor inflammatory molecules were inhibited in IL-17R-/- mice. We found that pre-existing inflammation in the skin increased the susceptibility to tumor growth, which was associated with increased development of tumor specific IL-17 producing T cells. This inflammation induced susceptibility to tumor growth was abrogated in IL-17R-/- mice. Finally, neutralizing IL-17 in mice that had already developed chemical carcinogen induced skin tumors could inhibit inflammation mediated tumor progression at late stages. These results demonstrate that IL-17 mediated inflammation is an important mechanism for inflammation mediated promotion of tumor development. The study has major implications for targeting IL-17 in prevention and treatment of tumors.
References
[1]
Dunn GP, Old LJ, Schreiber RD (2004) The Three Es of Cancer Immunoediting. Annual Review of Immunology 22: 329–360.
Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715.
[4]
Carlos TM (2001) Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc Biol 70: 171–184.
[5]
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology 29: 235–271.
[6]
Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211–217.
[7]
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860.
[8]
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 313: 1960–1964.
[9]
Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer 4: 71.
[10]
Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904–5912.
[11]
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436–444.
[12]
Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional Specialization of Interleukin-17 Family Members. Immunity 34: 149–162.
[13]
Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10: 479–489.
[14]
Zou W, Restifo NP (2010) TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10: 248–256.
[15]
Yusuf N, Nasti TH, Katiyar SK, Jacobs MK, Seibert MD, et al. (2008) Antagonistic Roles of CD4+ and CD8+ T-Cells in 7,12-Dimethylbenz(a)anthracene Cutaneous Carcinogenesis. Cancer Res 68: 3924–3930.
[16]
Maniati E, Soper R, Hagemann T (2010) Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29: 5653–5662.
[17]
Chae W-J, Gibson TF, Zelterman D, Hao L, Henegariu O, et al. (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proceedings of the National Academy of Sciences 107: 5540–5544.
[18]
Wang L, Yi T, Zhang W, Pardoll DM, Yu H (2010) IL-17 Enhances Tumor Development in Carcinogen-Induced Skin Cancer. Cancer Research 70: 10112–10120.
[19]
Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, et al. (2009) The tumor-promoting actions of TNF-a involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Inv 119: 3011–3023.
Yusuf N, Timares L, Seibert MD, Xu H, Elmets CA (2007) Acquired and innate immunity to polyaromatic hydrocarbons. Toxicology and Applied Pharmacology 224: 308.
[22]
Owens DM, Wei SJC, Smart RC (1999) A multihit, multistage model of chemical carcinogenesis. Carcinogenesis 20: 1837–1844.
[23]
Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, et al. (1999) Mice deficient in tumor necrosis factor-[alpha] are resistant to skin carcinogenesis. Nat Med 5: 828.
[24]
Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, et al. (2007) Interleukin-1{beta}-Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen-Induced Tumors. Cancer Res 67: 1062–1071.
[25]
Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, et al. (2002) Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 99: 12483–12488.
[26]
Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, et al. (2002) Deficiency of Either Cyclooxygenase (COX)-1 or COX-2 Alters Epidermal Differentiation and Reduces Mouse Skin Tumorigenesis. Cancer Res 62: 3395–3401.
[27]
Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, et al. (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205: 275–285.
[28]
Gebhardt C, Németh J, Angel P, Hess J (2006) S100A8 and S100A9 in inflammation and cancer. Biochemical Pharmacology 72: 1622–1631.
[29]
Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, et al. (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205: 2235–2249.
[30]
Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, et al. (2008) Protective Role of Toll-like Receptor 4 during the Initiation Stage of Cutaneous Chemical Carcinogenesis. Cancer Res 68: 615–622.
He D, Li H, Yusuf N, Elmets CA, Li J, et al. (2010) IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells. J Immunol 184: 2281–2288.
[35]
Murugaiyan G, Saha B (2009) Protumor vs Antitumor Functions of IL-17. J Immunol 183: 4169–4175.
[36]
Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15: 1016.
[37]
Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357–359.
[38]
Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362–373.
[39]
Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, et al. (2009) Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596–599.
[40]
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206: 1457–1464.
[41]
Dunn GP, Old LJ, Schreiber RD (2004) The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity 21: 137–148.
[42]
Kolls JK, Linden A (2004) Interleukin-17 Family Members and Inflammation. Immunity 21: 467–476.
[43]
Zlotnik A, Burkhardt AM, Homey B (2011) Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11: 597–606.
[44]
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? The Lancet 357: 539.
[45]
Whiteside TL (2006) The role of immune cells in the tumor microenvironment. Cancer Treat Res 130: 103–124.
[46]
Clevers H (2004) At the Crossroads of Inflammation and Cancer. Cell 118: 671–674.
[47]
Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162–174.
[48]
Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews 222: 162–179.
[49]
Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology 16: 53–65.
[50]
Ostrand-Rosenberg S, Sinha P (2009) Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. J Immunol 182: 4499–4506.
[51]
Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S (2009) Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells. J Immunol 183: 937–944.
[52]
Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908–7916.
[53]
Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18: 790–804.
[54]
Gupta RA, DuBois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11.
[55]
Backlund MG, Mann JR, DuBois RN (2005) Mechanisms for the Prevention of Gastrointestinal Cancer: The Role of Prostaglandin E 2. Oncology 69: 28–32.
[56]
Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, et al. (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931–939.
[57]
Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells. Cancer Res 67: 4507–4513.
[58]
Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, et al. (2008) Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells. J Immunol 181: 4666–4675.
[59]
Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8: 1369.
[60]
Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, et al. (2011) Contribution of IL-17-producing γδT cells to the efficacy of anticancer chemotherapy. J Exp Med 208: 491–503.
[61]
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, et al. (2009) T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. Immunity 31: 787.
[62]
Hsu H-C, Yang P, Wang J, Wu Q, Myers R, et al. (2008) Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9: 166–175.
[63]
He D, Wu L, Kim HK, Li H, Elmets CA, et al. (2006) CD8+ IL-17-Producing T Cells Are Important in Effector Functions for the Elicitation of Contact Hypersensitivity Responses. J Immunol 177: 6852–6858.
[64]
Kim HK, Zhang H, Li H, Wu ZT, Swisher S, et al. (2008) Slit2 Inhibits Growth and Metastasis of Fibrosarcoma and Squamous Cell Carcinoma. Neoplasia 10: 1411–1420.
